Why the study?
Does higher systemic exposure to atenolol increase the risk of adverse metabolic effects in hypertensive adults?
Does higher systemic exposure to atenolol increase the risk of adverse metabolic effects in hypertensive adults?
Higher systemic exposure to atenolol may be a risk factor for increased fasting plasma glucose levels, suggesting a pharmacokinetic basis for its adverse metabolic effects.
Answers are grounded in this paper and cite their sources.
May link atenolol exposure to fasting glucose changes in hypertension; hypothesis-generating, should not yet change practice.
Study Objective. To evaluate whether the level of systemic exposure to atenolol explains observed interindividual differences in adverse metabolic responses. Design. Open‐label, prospective, pharmacokinetic pilot substudy of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Setting. General clinical research center. Patients. Fifteen hypertensive adults (mean age 46 ± 8.9 yrs) who were enrolled in the PEAR study. Intervention. Patients received atenolol therapy for at least 8 weeks, with 5 of those weeks at a dosage of 100 mg/day and then underwent a 2–hour oral glucose tolerance test during a pharmacokinetic study visit. Measurements and Main Results. Twenty‐hour plasma atenolol concentrations were measured during the pharmacokinetic visit. Glucose and insulin levels were measured during the 2–hour oral glucose tolerance test, and fasting plasma lipid, glucose, and insulin levels were measured at baseline and after 8 weeks of atenolol treatment. A significant association was noted between atenolol area under the concentration‐time curve (AUC) and change in fasting glucose level when adjusted for covariates (p=0.0025); the effect was strongest in women. No significant relationship was noted between plasma atenolol concentration and glucose AUC during oral glucose tolerance testing (r=0.08, p=0.78), nor between atenolol AUC and change in triglyceride levels (r=0.13, p=0.63). Conclusion. Higher plasma atenolol exposure may be a risk factor for an increase in fasting plasma glucose level during atenolol treatment. These findings require confirmation in a larger sample.
No takes yet. Share an insight, caveat, or question.
Navare et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: